"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 4 | 6 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 4 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 6 | 7 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 2 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 7 | 8 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 4 | 5 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 3 | 5 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 2 | 5 |
| 2025 | 1 | 2 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. Clin Colorectal Cancer. 2026 Mar; 25(1):115-124.
-
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Rep Med. 2025 Apr 15; 6(4):102053.
-
Advanced-stage duodenal cancer in pregnancy. BMJ Case Rep. 2025 Jan 09; 18(1).
-
Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil. Nucleic Acids Res. 2024 Nov 11; 52(20):12534-12548.
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec; 44(12):1431-1443.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024 Jun; 23(2):118-127.e6.
-
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun. 2024 01 02; 15(1):79.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 07 27; 389(4):322-334.